Paradoxically decreased HDL-cholesterol levels associated with rosiglitazone therapy

Annals of Pharmacotherapy

Volumn 40, Issue 9, 2006, Pages 1672-1676

  Gutschi, L Maria ^a   Malcolm, Janine C ^b,c   Favreau, Colette M ^b   Ooi, Teik Chye ^b  

^a Canadian Forces Health Services   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c UNIVERSITY OF OTTAWA   (Canada)

Author keywords

HDL cholesterol; Hyperlipidemia; Rosiglitazone; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN SENSITIZING AGENT; LIPID; PIOGLITAZONE; ROSIGLITAZONE; TRIACYLGLYCEROL;

ADULT; ARTICLE; CASE REPORT; CHOLESTEROL BLOOD LEVEL; DIABETES MELLITUS; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DISEASE COURSE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HUMAN CELL; INSULIN SENSITIVITY; LIPID METABOLISM; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PARADOXICAL DRUG REACTION; PRIORITY JOURNAL; PROBABILITY;

CHOLESTEROL, HDL; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; HUMANS; MALE; MIDDLE AGED; THIAZOLIDINEDIONES;

EID: 33748328200     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1H020     Document Type: Article

References (14)

1. Yki-Jarvinen H. Pathogenesis of non-insulin dependent diabetes mellitus. Lancet 1994;343:91-5.
2. Nesto RW. Correlation between cardiovascular disease and diabetes mellitus: current concepts. Am J Med 2004;116(suppl 5A):11S-22S.
3. Harmel ALP, Kendall DM, Buse JB. Impact of adjunctive thiazolidinedione therapy on blood lipid levels control in patients with type 2 diabetes. Curr Med Res Opin 2004;20:215-33.
4. Olansky L, Marchetti A, Lau H. Multicenter retrospective assessment of thiazolidinedione monotherapy and combination therapy in patients with type 2 diabetes: comparative subgroup analysis of glycemic control and blood lipid levels. Clin Ther 2003;25(suppl B):B64-80.
5. Boyle PJ, King AB, Olansky L, Marchetti A, Lau H, Mugar B. Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: a retrospective review of randomly selected medical records. Clin Ther 2002;24:378-96.
6. Goldberg RB, Kendall DM, Deeg MA, Buse JB, Zagar AJ, Pinaire JA. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2004;28:1547-54.
7. Yki-Jarvimen H. Thiazolidinediones. N Engl J Med 2004;351:1106-18.
8. Sarker A, Semple RK, Dinneen SF, O'Rahilly S, Martin SC. Severe hypo-alpha-lipoproteinemia during treatment with rosiglitazone. Diabetes Care 2004;27:2577-80.
9. Health Canada. Rosiglitazone (Avandia): decreased high-density lipoprotein cholesterol levels. Canadian Adverse Drug Reaction Letter 2005;15(3). www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/carn-bcei_v15n3_e.html#3 (accessed 2006 Mar 27).
10. Ebcioglu Z, Morgan J, Carey C, Capuzzi D. Paradoxical lowering of high-density lipoprotein cholesterol level in 2 patients receiving fenofibrate and a thiazolidinedione. Ann Intern Med 2003;139:W80.
11. Sacks FM. The role of high-density lipoprotein (HDL) cholesterol in the prevention and treatment of coronary heart disease: expert group recommendations. Am J Cardiol 2002;90:139-43.
12. Ogilvie BW, Zhang D, Li W, et al. Gucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: implications for drug-drug interaction. Drug Metab Dispos 2006;34:191-7.
13. Wagner JA, Larson PJ, Weiss S, et al. Individual and combined effects of peroxisome proliferator-activated receptor and γ agonists, fenofibrate and rosiglitazone, on biomarkers of lipid and glucose metabolism in healthy nondiabetic volunteers. J Clin Pharmacol 2005;45:504-13.
14. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.